For more information about clinical research PAREXEL services go to:About PAREXELPAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communication and guidance to the world’s pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that 9180 time – to-market and peak – market penetration, PAREXEL has developed significant expertise in the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials, medical education and reimbursement. Perceptive Informatics, a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, the clinical development the clinical development pharmacy online prescription . Headquartered in Boston, Massachusetts, PAREXEL operates in 71 locations in 52 countries around the world and has over 9,180 employees.
PAREXEL International CorporationPAREXEL International Corporation , a leading global biopharmaceutical service provider, announced that it formed an alliance with Safe Implementation of Treatments in Stroke International, the world’s largest network of clinical sites with specialized functions in the field of stroke. Through this alliance SITS PAREXEL clients benefit from access to more than 800 sites in 40 countries who are dedicated to the treatment of patients with acute stroke and for the implementation of Phase II – IV clinical trials of stroke. ‘According to the World Health Organization, 15 million people suffer a stroke worldwide each year, and, with the aging of the population On a global basis PAREXEL turning with respect to an increasing number of clinical programs are focused on the development of new stroke treatments, ‘according to Mark A. Goldberg, Chief Operating Officer, PAREXEL. We are delighted our profound central nervous system therapeutic area to combine expertise with highly specialized skills perform SITS customers stroke trials more efficient. On a global basis ‘.
Ten thousand and one levels, the cardiovascular risk to occur in patients increase with heart conditions despite considerable reductions in LDL – cholesterol.
This study team analyzed a total 10,001 patients with coronary artery disease , all cause mortality either atorvastatin 10 mg and 80 mg atorvastatin daily for an primary composite endpoint of the received death from coronary heart sickness, nonfatal myocardial infarction , resuscitation after cardiac arrest, fatal or nonfatal apoplexy.